<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592161</url>
  </required_header>
  <id_info>
    <org_study_id>B110051</org_study_id>
    <nct_id>NCT02592161</nct_id>
    <nct_alias>NCT01771510</nct_alias>
  </id_info>
  <brief_title>Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis</brief_title>
  <official_title>A Randomized, Single Center, Double Blind, Parallel, Placebo-controlled Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Health Industry Development Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Health Industry Development Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, single center, double blind, parallel, placebo-controlled, clinical study of
      efficacy and safety of Chung A Won and placebo for 24 weeks three times a day on the
      improvement of osteoporosis and symptoms in Women's older than 50 patients with osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of T-score of bone mineral density(QCT)</measure>
    <time_frame>baseline, After 24 weeks(Â± 3 days) from the baseline of the trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of T-score</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks from the baseline of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of osteoporosis-related indicators of blood tests</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of ODI(Oswestry Disability Index)</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of QVAS(Quardruple Visual Analog Scale)</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of kupperman index</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of shin-huh symptoms</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of quality of life using SF-36</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental</intervention_name>
    <description>Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)
Three times a day, oral administration for 24weeks</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Chung A Won</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1)Female more than 50 years old in osteoporosis

        Exclusion Criteria:

          1. Wash out peroid: using agents more than 3 months against osteoporosis

          2. Subject who takes drugs that may affect the clinical trials (Corticosteroids,
             anticonvulsants, tranquilizers, antidepressants, hypnotic, diuretic)

          3. Subject who has a chronic liver disease, thyroid disease and chronic renal disease

          4. Subject who is chronic alcoholics and undernourished

          5. Other conditions were not suitable in study : Severe physical defects mental defects

          6. Pregnant woman

          7. Subject who is not calibrated hypercalcemia/hypocalcemia

          8. Secondary osteoporosis : Subject who takes drugs(Glucocorticoid, Diabetes Medications)

          9. Subject who has 60% more fracture risk in FRAX(WHO fracture risk assessment tool)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea Health Industry Development Institute</investigator_affiliation>
    <investigator_full_name>Hyun Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

